A recent study suggested that CDK4/6 inhibitors could downregulate DNMT1 expression in Treg cells and trigger anti‐tumor immunity,76 suggesting that targeting PAX6 might be of clinical value to tumor immunotherapy in the future. This evidence concerns the gene CDK4 and neoplasm.